LYriCAN+: renewal of the Lyon SIRIC
Publié le 20/02/2023
The Lyon Integrated Cancer Research Site (LYriCAN+) has just been re-labeled by the French National Cancer Institute (INCa). This is a great success for the Lyon site, which has been accredited since 2011, and demonstrates the excellence of the work carried out in its research laboratories and its HCL and CLB hospital sites. The CRCL research teams are once again highly involved in each of the 3 integrated research programs.
LYriCAN+ project was in competition with 14 other projects at the national level and is one of the 8 SIRICs accredited in France. It is headed by Professor Jean-Yves Blay, Director General of the Lyon and Rhône-Alpes Cancer Center.
3 new programs to better understand cancer
LYriCAN+ proposes three new ambitious integrated research programs that will explore the progression of cancer from pre-neoplastic to metastatic stages:
- identification of new targets in early cancer development to improve treatment of preneoplastic lesions;
- new imaging tools, new physical treatments;
- characterization and treatment of tumor and immune cell plasticity in the clinic.
As in previous SIRIC accreditations, the development of these programs relies significantly on the research work carried out at the CRCL with 13 of its teams integrating at least one of the three integrated research programs.